Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions
暂无分享,去创建一个
[1] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[2] Ping Zhang. Model Selection Via Multifold Cross Validation , 1993 .
[3] N. Devlin,et al. The Influence of Cost-Effectiveness and Other Factors on NICE Decisions , 2010, Health economics.
[4] Jing Jing Li,et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.
[5] F Dannegger,et al. Tree stability diagnostics and some remedies for instability. , 2000, Statistics in medicine.
[6] M. Knapp,et al. Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making , 2014, The European Journal of Health Economics.
[7] Hal R. Varian,et al. Big Data: New Tricks for Econometrics , 2014 .
[8] Stirling Bryan,et al. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. , 2007, Health economics.
[9] Ron Kohavi,et al. A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.
[10] K. Baumstarck,et al. Exploring the Response Shift Effect on the Quality of Life of Patients with Schizophrenia , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] James Raftery,et al. NICE and the challenge of cancer drugs , 2009, BMJ : British Medical Journal.
[12] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[13] K. Hornik,et al. party : A Laboratory for Recursive Partytioning , 2009 .
[14] W. Rogowski,et al. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. , 2013, Health policy.
[15] K. Fischer,et al. A systematic review of coverage decision-making on health technologies-evidence from the real world. , 2012, Health policy.
[16] Roman Timofeev,et al. Classification and Regression Trees(CART)Theory and Applications , 2004 .
[17] M. Drummond,et al. Public funding of new cancer drugs: Is NICE getting nastier? , 2009, European journal of cancer.
[18] Leonie Segal,et al. Fixing the game: are between-silo differences in funding arrangements handicapping some interventions and giving others a head-start? , 2010, Health economics.
[19] Philip S. Yu,et al. Top 10 algorithms in data mining , 2007, Knowledge and Information Systems.
[20] Martin Knapp,et al. Decision making by NICE: examining the influences of evidence, process and context , 2013, Health Economics, Policy and Law.
[21] Nancy J Devlin,et al. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. , 2006, Health policy.
[22] S. Hill,et al. Cost-effectiveness and resource allocation - Reply , 2006 .
[23] R. Foy,et al. Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold , 1999, BMJ.
[24] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[25] D. Hughes,et al. Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.
[26] Jing Jing Li,et al. The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[27] Kalipso Chalkidou,et al. Evidence and values: paying for end-of-life drugs in the British NHS , 2012, Health Economics, Policy and Law.
[28] Sue P O'Malley. The Australian experiment: the use of evidence based medicine for the reimbursement of surgical and diagnostic procedures (1998–2004) , 2006, Australia and New Zealand health policy.
[29] C. McCabe,et al. Public healthcare resource allocation and the Rule of Rescue , 2008, Journal of Medical Ethics.
[30] D. Menon,et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] M. Buxton,et al. Searching for cost effectiveness thresholds in the NHS. , 2009, Health policy.
[32] D. Mortimer,et al. Review of Australian health economic evaluation – 245 interventions: what can we say about cost effectiveness? , 2008, Cost effectiveness and resource allocation : C/E.
[33] A. Harris,et al. Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.